PE-22-28

It pairs one of the cleaner mechanisms in the grey-market peptide world with a completely empty human file. The TREK-1 to depression link is real and well-characterized, the rodent antidepressant and neurogenesis data is genuine, and the speed of onset is the kind of thing that makes the whole class exciting, per Mazella 2010 and Djillani 2017. But there are zero human trials, the dose response is biphasic in a way that can reverse the effect, and TREK-1 is expressed in the heart, pancreas, and gut, so a systemic blocker carries uncharacterized off-target risk, per Hivelin 2016. Promising mechanism, no human proof, grey-market.

✅ Best for: Researchers and very experienced self-experimenters who fully understand that this is preclinical and act accordingly. People who grasp the biphasic-dosing trap and would not assume a higher dose is better. Anyone tracking the TREK-1 antidepressant story for its scientific interest rather than treating it as a ready tool. Users who accept that grey-market sourcing means unverified purity, sterility, and identity on top of an already unvalidated compound.

❌ Avoid if: You want an evidence-backed mood or antidepressant tool, since none of the human proof exists, and options like Semax at least have human use behind them. You have any cardiovascular condition, diabetes or blood-sugar issues, or gut conditions, since TREK-1 sits in all those tissues and human safety is unknown. You would be tempted to push the dose upward, since that can flip the effect. You cannot verify source quality, since contamination risk may exceed the intrinsic pharmacological risk. You expect a settled protocol, since there is no validated human dose.